Sarcoma is not one disease. Soft-tissue sarcomas and bone sarcomas include many histologic subtypes, can arise in the extremities, retroperitoneum, abdomen, pelvis, chest or other sites, and often require different combinations of surgery, radiation and systemic therapy. German university sarcoma centers publish multidisciplinary pathways in which pathology, radiology, surgical subspecialties, medical oncology and radiation oncology review the case together. International patients should therefore seek a specialist sarcoma-board review before choosing a hospital or requesting one procedure in isolation.
Expert pathology is central because sarcoma subtype changes treatment
Sarcomas are rare and histologically diverse. Charité, Freiburg and Heidelberg all organize care through specialist sarcoma structures, and Heidelberg lists dedicated reference pathology within its certified center. Before travelling, ask whether the German team wants original pathology slides or blocks reviewed, especially when the subtype, grade or diagnosis remains uncertain.
Imaging must define the tumor before biopsy or surgery planning
Freiburg describes contrast-enhanced MRI as a core investigation for unclear soft-tissue tumors, while additional CT or other staging may be required according to site and histology. The sequence matters: poorly planned biopsy or unplanned excision can complicate later definitive surgery, so specialist review should happen early when possible.
The anatomical site determines which surgeons need to be involved
Charité's sarcoma center treats tumors of the extremities, abdomen, retroperitoneum and pelvis through a multidisciplinary network. Heidelberg's certified center integrates orthopedic, visceral, plastic and thoracic surgeons, while Freiburg separates pathways for soft-tissue, bone and abdominal sarcomas. A hospital should be selected for the exact anatomical problem rather than the word 'sarcoma' alone.
Surgery often aims for complete tumor removal while preserving function
For resectable sarcoma, surgery can be a central curative-intent treatment. Charité documents modern limb-preserving approaches and emphasizes function and quality of life, while Freiburg and Heidelberg coordinate tumor surgery with reconstructive, orthopedic or visceral expertise when needed. The operative plan should specify expected margins, reconstruction and the functional trade-offs before travel.
Radiotherapy can be used before or after surgery in selected soft-tissue sarcomas
Radiation timing depends on histology, site, grade, surgical margins and anticipated morbidity. The sarcoma board should determine whether radiotherapy is appropriate and whether preoperative or postoperative treatment is preferred rather than treating radiation as an automatic step for every sarcoma.
Systemic treatment is subtype- and stage-dependent
Medical oncology can be important for metastatic disease, selected high-risk soft-tissue sarcomas and specific bone sarcoma pathways. Drug choice depends on histology, molecular findings, previous treatment, organ function and current evidence. A static list of chemotherapy or targeted drugs is therefore less useful than a current specialist recommendation for the exact sarcoma subtype.
Retroperitoneal and abdominal sarcomas need experienced complex-surgery planning
Large retroperitoneal or abdominal sarcomas can involve adjacent organs and major vessels and may require multivisceral surgery. Charité and Freiburg both publish specialist pathways for abdominal or retroperitoneal sarcomas. International patients should send full cross-sectional imaging so the team can assess resectability and the likely surgical scope before proposing a visit.
Bone sarcomas require orthopedic-oncology expertise
Bone sarcoma treatment can require tumor orthopedics, reconstructive planning, medical oncology and radiotherapy depending on subtype and location. Heidelberg's DKG-certified sarcoma center explicitly includes bone sarcomas, and Freiburg routes bone sarcoma care through tumor orthopedics within its sarcoma program.
Records to send before travelling
The sarcoma team should be able to confirm diagnosis, anatomical extent and prior treatment before deciding whether a German visit is useful.
- Original pathology report with histologic subtype and grade when available
- Pathology slides or blocks for expert review if requested
- MRI of the primary tumor region in DICOM format
- CT chest and other staging imaging when already performed
- Reports from previous biopsy or surgery including operative notes
- Details of any prior radiotherapy, chemotherapy or targeted treatment
- Relevant molecular testing when already available
- Current medication and important comorbidities
- A clear question about pathology review, surgery, radiotherapy, systemic therapy, recurrence or second opinion
Follow-up should be coordinated with the sarcoma center
Surveillance depends on subtype, grade, stage, treatment and recurrence risk. Before returning home, clarify which MRI or CT studies are needed, how postoperative function or reconstruction will be monitored, and when new imaging should be returned to the German sarcoma team for review.
Sources and review
This guide was last source-reviewed on 2026-08-30.
- Center for Sarcomas – multidisciplinary soft-tissue and bone tumor care — Charité – Universitätsmedizin Berlin ↗
- Sarcoma Center – interdisciplinary pathways — University Medical Center Freiburg ↗
- Freiburg soft-tissue sarcoma center DKG certification, March 2026 — University Medical Center Freiburg ↗
- Sarcoma Center Heidelberg – DKG-certified bone and soft-tissue sarcoma center — NCT Heidelberg / Heidelberg University Hospital ↗
- Sarcoma Center Heidelberg – patient appointments and specialist disciplines — NCT Heidelberg / Heidelberg University Hospital ↗